An independent panel convened by the NIH has concluded that many men with localized, low-risk prostate cancer should be closely monitored, permitting treatment to be delayed until warranted by disease progression.
Read MoreA new Webinar will review the current role of PSA biomarkers, strategies for increasing specificity of PSA testing, and offer expert advice for optimizing risk assessment protocols.
Read MoreSome argue that there is not enough evidence to suggest PSA’s use as a screening tool improves patient survival, but others believe the test has been instrumental in reducing mortality from prostate cancer in the US.
Read More
BioCare Medical LLC offers a new look at prostate cancer diagnosis.
Read MoreGenomic Health Inc announces the first results of a large prostate cancer study that identified 295 genes strongly associated with clinical recurrence following radical prostatectomy.
Read More